Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough

Moderna’s market valuation fell to $51.5B as of Thursday, down more than $18B from Wednesday’s $69.6B closing valuation. The abrupt drawdown signals deteriorating market sentiment toward the biotech name, though the excerpt provides no explicit fundamental driver.

Analysis

Moderna’s market valuation fell to $51.5B as of Thursday, down more than $18B from Wednesday’s $69.6B closing valuation. The abrupt drawdown signals deteriorating market sentiment toward the biotech name, though the excerpt provides no explicit fundamental driver.